TSBX — Turnstone Biologics Income Statement
0.000.00%
HealthcareMicro Cap
- $54.81m
- -$23.03m
- $19.31m
Annual income statement for Turnstone Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 101 | 73.3 | 19.3 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Total Operating Expenses | 68.3 | 105 | 78.3 |
Operating Profit | 33 | -31.6 | -59 |
Other Net Non Operating Costs | |||
Net Income Before Taxes | 33.7 | -30.7 | -55.5 |
Provision for Income Taxes | |||
Net Income After Taxes | 33.3 | -30.8 | -55.2 |
Net Income Before Extraordinary Items | |||
Net Income | 33.3 | -30.8 | -55.2 |
Adjustments to Net Income | |||
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | 3.48 | -31 | -55.2 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | 0.157 | -1.4 | -4.67 |
Dividends per Share |